Following U.S. Stocks were among the “Top Losers” during Monday’s trade: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Comstock Resources Inc (NYSE:CRK), Approach Resources Inc (NASDAQ:AREX), Gastar Exploration Inc (NYSEMKT:GST)
Their insights are depicted underneath:
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)’s shares dwindled -6.83%, and closed at $0.553.
Through PRNewswire, ImmunoCellular Therapeutics, Ltd. (IMUC), declared financial results for the fourth quarter and year ended December 31, 2014.
For the year ended December 31, 2014, ImmunoCellular incurred a net loss of $9.4 million, or $0.16 per basic and diluted share, contrast to a net loss of $8.8 million, or $0.16 per basic and diluted share, for the year ended December 31, 2013. During 2014, ImmunoCellular raised its research and development expenditures related to ICT-121 and ICT-140 and continued to incur ICT-107 Phase 2 expenses related to patient follow-up and data analysis. These expenses reduced during the second half of the year as the study is complete. Also, during 2014 ImmunoCellular recognized a gain of $530,000 related to the revaluation of its warrant derivatives and a charge of $654,000 related to stock-based compensation. The loss for 2013 comprised of a gain of $642,000 related to the revaluation of its warrant derivatives and a charge of $724,000 related to stock-based compensation.
For the quarter ended December 31, 2014, ImmunoCellular incurred a net loss of $2.1 million, or $0.03 per basic and diluted share, contrast to net revenue of $117,000, or $0.00 per basic and diluted share, for the quarter ended December 31, 2013. The net revenue for the quarter ended December 31, 2013, reflects a gain of $2.7 million related to the revaluation of ImmunoCellular’s warrant derivatives.
In February of 2015, ImmunoCellular accomplished an underwritten public offering following which it sold 26,650,000 shares of ordinary stock and warrants to purchase 18,655,000 shares of ordinary stock, at a combined public offering price of $0.60 per share. The net proceeds from the offering were about $14.6 million, after deducting the underwriting discount and offering expenses payable by ImmunoCellular. The warrants have an exercise price of $0.66 per share and a term of 60 months from the date of issuance. The warrants also provide for a weighted-average adjustment to the exercise price if the Corporation issues additional shares of ordinary stock at a price per share less than then effective exercise price of the warrants, subject to certain exceptions.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage corporation that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.
Gastar Exploration Inc (NYSEMKT:GST), dropped -6.79%, and closed at $2.61.
Through PRNewswire, Gastar Exploration Inc. (GST), released that it has declared monthly cash dividends on its 8.625% Series A Preferred Stock (“Series A Preferred Stock”) and its 10.75% Series B Preferred Stock (“Series B Preferred Stock”) for March 2015.
The dividend on the Series A Preferred Stock is payable on March 31, 2015 to holders of record at the close of business on March 13, 2015. The March 2015 dividend payment will be an annualized 8.625% per share, which is equivalent to $0.179688 per share, based on the $25.00 per share liquidation preference of the Series A Preferred Stock. The Series A Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “GST.PRA.”
The dividend on the Series B Preferred Stock is payable on March 31, 2015 to holders of record at the close of business on March 13, 2015. The March 2015 dividend payment will be an annualized 10.75% per share, which is equivalent to $0.223958 per share, based on the $25.00 per share liquidation preference of the Series B Preferred Stock. The Series B Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “GST.PRB.”
Gastar Exploration Inc. is an independent energy corporation engaged in the exploration, development and production of oil, condensate, natural gas and natural gas liquids in the United States. Gastar’s principal business activities comprise the identification, attainment, and subsequent exploration and development of oil and natural gas properties with an emphasis on unconventional reserves, such as shale resource plays.
Comstock Resources Inc (NYSE:CRK), declined -6.76%, and closed at $4.55. The stock has the beta value of 1.82, and its volatility for the week is 9.44%, while for the month it is 9.88%. The company has the market capitalization of $232.42M. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).
Comstock Resources, Inc., an independent energy corporation, attains, develops, explores, and produces oil and natural gas properties in the United States.
Approach Resources Inc (NASDAQ:AREX), dipped -6.64%, and closed at $6.61.
Approach Resources, Inc. (AREX), declared that the Corporation took part in one-on-one investor meetings at the Simmons & Corporation International Fifteenth Annual Energy Conference on Thursday, March 5, 2015.
Approach Resources Inc., an independent energy corporation, focuses on the exploration, development, production, and attainment of unconventional oil and gas reserves in the United States.
